New Drug Candidate SCYX-5070 for Treating Sleeping Sickness
Author Information
Author(s): Mercer Luke, Bowling Tana, Perales Joe, Freeman Jennifer, Nguyen Tien, Bacchi Cyrus, Yarlett Nigel, Don Robert, Jacobs Robert, Nare Bakela
Primary Institution: SCYNEXIS Inc.
Hypothesis
Can 2,4-diaminopyrimidines serve as effective inhibitors of Trypanosoma brucei?
Conclusion
The study found that SCYX-5070 is a potent inhibitor of Trypanosoma brucei and shows promise as a treatment for human African trypanosomiasis.
Supporting Evidence
- SCYX-5070 cured acute trypanosomiasis in mice without toxicity.
- 2,4-diaminopyrimidines showed a good pharmacological profile against trypanosomatid protozoans.
- MAPKs and CRKs were identified as potential molecular targets for SCYX-5070.
Takeaway
Scientists discovered a new medicine that can kill the germs causing sleeping sickness in mice, which could help people who are sick.
Methodology
The study involved in vitro and in vivo testing of SCYX-5070 against Trypanosoma brucei, including time kill assays and efficacy in a mouse model.
Limitations
The study primarily focused on in vitro and mouse models, which may not fully represent human responses.
Participant Demographics
Female Swiss Webster mice were used in the animal model.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website